Press
| Date | Announcement | |
|---|---|---|
| 19 March 2009 | Positive Phase I Clinical Results for Treatment of Cat Dander Allergy ... |
|
| 10 November 2008 | ILIT Proof of Concept published in PNAS The proof of concept on intralymphatic allergen to improve allergy immunotherapy has been published in the Preceeding... |
|
| 12 September 2008 | Financing and clinical study enroled ImVisioN Therapeutics starts Phase I clinical trial of IVN201 against cat dander allergy and raises CHF 4.6 M... |
|
| 6 February 2007 | EU patent for MAT technology granted ImVisioN Therapeutics strengthens patent position (Not for distribution in the United States) EU... |
|
| 3 March 2006 | Exclusive license from MannKind Corporation obtained ImVisioN GmbH obtains an exclusive license from MannKind Corporation to patents covering the intralymphatic administr... |
|
| 23 May 2005 | Martin Steiner appointed as CEO Hanover (Germany), May 23, 2005. ImVisioN GmbH announced that it has appointed Martin Steiner as Chief Executiv... |
|
| 3 May 2005 | BioVisioN AG sells its subsidiary ImVisioN GmbH to Nextech Venture, L.P. German biotech company BioVisioN AG has sold its spin-off, ImVisioN GmbH, to the Swiss based life science investment fir... |
|
| 6 December 2004 | BioVisioN AG spins off new enterprise with peptide vaccine portfolio Hannover, 6 December 2004 BioVisioN announces the spin-off of a drug portfolio for causative treatment of allergic di... |
|
Press Resources